Haridwar Today

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Insights, Epidemiology, and Market Forecast – 2036.” This comprehensive report provides an in-depth understanding of Non-Cystic Fibrosis Bronchiectasis Epidemiology, NCFB Market Size, Bronchiectasis Market Forecast, current treatment landscape, NCFB Clinical Trials, Non-Cystic Fibrosis Bronchiectasis Pipeline, emerging Bronchiectasis Therapies, and market dynamics across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan (7MM).

Key Takeaways from the Non-Cystic Fibrosis Bronchiectasis Market

• The Non-Cystic Fibrosis Bronchiectasis Market Size across the 7MM is expected to witness remarkable growth through 2036, driven by increasing disease prevalence, improved diagnostic capabilities, growing adoption of targeted therapies, and the anticipated launch of multiple emerging Bronchiectasis Drugs. According to DelveInsight estimates, the 7MM market size is projected to increase from approximately USD 1.37 billion in 2022 to nearly USD 5.77 billion by 2036, reflecting strong commercial potential for innovative therapies.

• According to DelveInsight estimates, the diagnosed prevalent cases of Non-Cystic Fibrosis Bronchiectasis in the 7MM exceeded 1 million patients in 2025 and are expected to continue increasing throughout the forecast period, driven by enhanced physician awareness, wider use of HRCT imaging, and improved disease recognition.

• The United States accounted for the largest Non-Cystic Fibrosis Bronchiectasis Market in 2025 and is expected to maintain its dominance during the forecast period owing to higher diagnosis rates, greater adoption of novel therapies, increasing healthcare expenditure, and favorable reimbursement policies. In 2025, the US reported approximately 400,000 diagnosed prevalent cases of NCFB.

• Among the European countries, the United Kingdom recorded the highest diagnosed prevalence of Non-Cystic Fibrosis Bronchiectasis, with approximately 235,000 diagnosed cases in 2025, followed by Spain, highlighting the growing disease burden across Europe.

• The report estimates that approximately 435,000 moderate cases of NCFB were reported across the 7MM in 2025, representing the largest disease severity segment and emphasizing the need for effective disease-modifying treatment options.

• Among patients with microbiologically confirmed disease, Pseudomonas aeruginosa remains one of the most clinically significant pathogens associated with recurrent exacerbations and disease progression. In Japan alone, nearly 27,000 diagnosed cases of Pseudomonas aeruginosa-associated NCFB were reported in 2025.

• A major milestone for the Bronchiectasis Treatment Market occurred in August 2025, when the US FDA approved BRINSUPRI (brensocatib) as the first-in-class, oral, once-daily therapy for adults and adolescents aged 12 years and older with Non-Cystic Fibrosis Bronchiectasis, significantly transforming the treatment landscape.

• Leading Non-Cystic Fibrosis Bronchiectasis Companies, including Insmed, CSL Behring, Verona Pharma, Renovion, and others, are actively advancing innovative Bronchiectasis Therapies aimed at reducing exacerbations, improving lung function, controlling chronic airway inflammation, and enhancing patients’ quality of life.

• The promising Non-Cystic Fibrosis Bronchiectasis Pipeline includes BRINSUPRI (brensocatib), CSL787, Nebulized Ensifentrine, ARINA-1 (RVN-301), and several additional investigational therapies expected to reshape the future NCFB Market through targeted disease-modifying approaches.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-market

Key Factors Driving the Non-Cystic Fibrosis Bronchiectasis Market

Rising Disease Prevalence and Improved Diagnosis: The prevalence of Non-Cystic Fibrosis Bronchiectasis (NCFB) is steadily increasing worldwide, particularly among elderly individuals and women. Improved physician awareness, widespread utilization of high-resolution computed tomography (HRCT), and better recognition of chronic respiratory symptoms have significantly enhanced diagnosis rates. Earlier diagnosis enables timely therapeutic intervention, thereby contributing to the growth of the Non-Cystic Fibrosis Bronchiectasis Market.

Growing Need for Disease-Modifying Therapies: Conventional treatment strategies primarily focus on symptom management through antibiotics, bronchodilators, corticosteroids, airway clearance techniques, and physiotherapy. However, these therapies have limited ability to alter disease progression. The approval of BRINSUPRI (brensocatib) as the first disease-modifying therapy represents a major breakthrough and is expected to reshape the Bronchiectasis Treatment Market while encouraging further innovation.

Increasing Burden of Chronic Airway Inflammation and Recurrent Exacerbations: Persistent neutrophilic inflammation, chronic bacterial colonization, recurrent pulmonary infections, and progressive lung damage continue to impose a substantial healthcare burden on patients with NCFB. Frequent exacerbations lead to repeated hospitalizations, declining lung function, and reduced quality of life, highlighting the need for innovative therapies capable of reducing inflammation and preventing disease progression.

Expanding Pipeline of Targeted Respiratory Therapies: Pharmaceutical companies are increasingly investing in innovative Bronchiectasis Drugs that target neutrophilic inflammation, mucus clearance, airway remodeling, and chronic infection. The growing pipeline of disease-modifying therapies is expected to significantly improve long-term clinical outcomes and accelerate expansion of the NCFB Treatment Market during the forecast period.

Non-Cystic Fibrosis Bronchiectasis Competitive Landscape

• The Non-Cystic Fibrosis Bronchiectasis Pipeline is rapidly evolving with multiple innovative therapies being evaluated in mid- and late-stage clinical development. Companies including Insmed, CSL Behring, Renovion, Verona Pharma, and others are focused on developing novel Bronchiectasis Therapies that address chronic airway inflammation, mucus accumulation, bacterial colonization, and recurrent exacerbations.

• Among the most significant advancements in the field is BRINSUPRI (brensocatib), developed by Insmed. Approved by the US FDA in August 2025, BRINSUPRI became the first-in-class, oral, once-daily dipeptidyl peptidase-1 (DPP-1) inhibitor indicated for patients with Non-Cystic Fibrosis Bronchiectasis. By inhibiting DPP-1 activation, the therapy reduces neutrophil serine protease activity, thereby decreasing airway inflammation and lowering the risk of pulmonary exacerbations.

• CSL787, being developed by CSL Behring, is another promising investigational therapy designed to modulate inflammatory pathways involved in neutrophil-dominant respiratory diseases. The therapy aims to reduce disease activity and prevent recurrent exacerbations while improving respiratory function in patients with chronic bronchiectasis.

• Nebulized Ensifentrine, developed by Verona Pharma, is an inhaled dual phosphodiesterase-3 and phosphodiesterase-4 (PDE3/PDE4) inhibitor that combines bronchodilatory and anti-inflammatory properties to improve lung function and reduce disease burden. Meanwhile, ARINA-1 (RVN-301) from Renovion is an innovative nebulized therapy designed to improve mucus clearance, reduce airway inflammation, and inhibit bacterial growth, offering a comprehensive approach to disease management.

• With the approval of BRINSUPRI and the continued advancement of multiple targeted respiratory therapies, the Non-Cystic Fibrosis Bronchiectasis Market is expected to experience significant innovation and sustained commercial growth through 2036.

Discover more about therapies set to grab major Non-Cystic Fibrosis Bronchiectasis Market share @ Non-Cystic Fibrosis Bronchiectasis Treatment Landscape

Recent Developments in the Non-Cystic Fibrosis Bronchiectasis Market

• In November 2025, Insmed announced that the European Commission approved BRINSUPRI (brensocatib 25 mg) for the treatment of Non-Cystic Fibrosis Bronchiectasis in patients aged 12 years and older who experienced two or more exacerbations during the previous 12 months.

• In August 2025, the US FDA approved BRINSUPRI (brensocatib) as the first-in-class oral, once-daily therapy for adults and adolescents with Non-Cystic Fibrosis Bronchiectasis, representing a landmark advancement in the bronchiectasis treatment landscape.

• In May 2025, Insmed presented 11 scientific abstracts at the American Thoracic Society (ATS) International Conference, including subgroup analyses from the Phase III ASPEN trial evaluating brensocatib in patients with NCFB, further strengthening evidence supporting its efficacy and safety.

• In February 2025, Verona Pharma announced continued enrollment in its Phase II clinical trial evaluating Nebulized Ensifentrine in patients with Non-Cystic Fibrosis Bronchiectasis to assess its safety and therapeutic efficacy.

• In April 2024, Renovion reported positive topline results from the Phase II CLIMB study evaluating ARINA-1 (RVN-301), supporting advancement into Phase III clinical development.

What is Non-Cystic Fibrosis Bronchiectasis (NCFB)?

Non-Cystic Fibrosis Bronchiectasis (NCFB) is a chronic, progressive respiratory disorder characterized by irreversible dilation of the bronchi resulting from persistent airway inflammation, impaired mucociliary clearance, and recurrent pulmonary infections. Patients commonly experience chronic productive cough, excessive sputum production, recurrent chest infections, shortness of breath, wheezing, fatigue, hemoptysis, and progressive decline in lung function. The disease is frequently associated with underlying conditions such as COPD, asthma, immunodeficiency, post-infectious lung disease, and idiopathic etiologies. Diagnosis primarily relies on high-resolution computed tomography (HRCT) together with pulmonary function testing, sputum cultures, bronchoscopy, and laboratory investigations. Current management includes antibiotics, bronchodilators, corticosteroids, airway clearance techniques, physiotherapy, vaccination, and supportive care. The emergence of disease-modifying therapies such as BRINSUPRI (brensocatib) and an expanding pipeline of targeted respiratory medicines is expected to transform the future Non-Cystic Fibrosis Bronchiectasis Treatment Market, improving long-term outcomes and quality of life for patients worldwide.

Non-Cystic Fibrosis Bronchiectasis Epidemiology Segmentation

The Non-Cystic Fibrosis Bronchiectasis epidemiology section provides insights into the historical and current Non-Cystic Fibrosis Bronchiectasis patient pool and forecasted trends for the leading markets. The Non-Cystic Fibrosis Bronchiectasis market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Total Diagnosed Prevalent Cases of Non-Cystic Fibrosis Bronchiectasis

• Gender-specific Diagnosed Prevalent Cases of Non-Cystic Fibrosis Bronchiectasis

• Severity-specific Diagnosed Prevalent Cases of Non-Cystic Fibrosis Bronchiectasis

• Etiology-specific Diagnosed Prevalent Cases of Non-Cystic Fibrosis Bronchiectasis

• Pathogen-specific Diagnosed Prevalent Cases of Non-Cystic Fibrosis Bronchiectasis

Scope of the Non-Cystic Fibrosis Bronchiectasis Market Report

• Therapeutic Assessment: Current marketed and emerging Non-Cystic Fibrosis Bronchiectasis Therapies

• Non-Cystic Fibrosis Bronchiectasis Market Dynamics: Key Market Forecast Assumptions of Emerging Non-Cystic Fibrosis Bronchiectasis Drugs and Market Outlook

• Key Companies: Insmed, CSL Behring, Verona Pharma, Renovion, Armata Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici, and others

• Key Therapies: BRINSUPRI (Brensocatib), CSL787, Nebulized Ensifentrine, ARINA-1 (RVN-301), AP-PA02, and others

• Competitive Intelligence Analysis: SWOT Analysis and Market Entry Strategies

• Unmet Needs, KOL’s Views, Analyst’s Views, Non-Cystic Fibrosis Bronchiectasis Market Access and Reimbursement

To know more about Non-Cystic Fibrosis Bronchiectasis companies working in the treatment market, visit @ Non-Cystic Fibrosis Bronchiectasis Clinical Trials and Therapeutic Assessment

Table of Contents

• Non-Cystic Fibrosis Bronchiectasis Market Report Introduction

• Executive Summary for Non-Cystic Fibrosis Bronchiectasis

• SWOT Analysis of Non-Cystic Fibrosis Bronchiectasis

• Non-Cystic Fibrosis Bronchiectasis Patient Share (%) Overview at a Glance

• Non-Cystic Fibrosis Bronchiectasis Market Overview at a Glance

• Non-Cystic Fibrosis Bronchiectasis Background and Overview

• Non-Cystic Fibrosis Bronchiectasis Epidemiology and Patient Population

• Country-Specific Patient Population of Non-Cystic Fibrosis Bronchiectasis

• Non-Cystic Fibrosis Bronchiectasis Current Treatment and Medical Practices

• Non-Cystic Fibrosis Bronchiectasis Unmet Needs

• Non-Cystic Fibrosis Bronchiectasis Emerging Therapies

• Non-Cystic Fibrosis Bronchiectasis Market Outlook

• Country-Wise Non-Cystic Fibrosis Bronchiectasis Market Analysis (2022–2036)

• Non-Cystic Fibrosis Bronchiectasis Market Access and Reimbursement of Therapies

• Non-Cystic Fibrosis Bronchiectasis Market Drivers

• Non-Cystic Fibrosis Bronchiectasis Market Barriers

• Non-Cystic Fibrosis Bronchiectasis Appendix

• Non-Cystic Fibrosis Bronchiectasis Report Methodology

• DelveInsight Capabilities

• Disclaimer

• About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/